REXAHN PHARMACEUTICALS, INC. (RNN) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 88 transactions totaling $4.8M, demonstrating a bearish sentiment with -$557.6K in net insider flow. The most recent transaction on Feb 28, 2019 involved a transaction of 2,375 shares valued at $0.
No significant insider buying has been recorded for RNN in the recent period.
No significant insider selling has been recorded for RNN in the recent period.
Based on recent SEC filings, insider sentiment for RNN is bearish with an Insider Alignment Score of 44/100 and a net flow of -$557.6K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at REXAHN PHARMACEUTICALS, INC. (RNN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading RNN stock, having executed 88 transactions in the past 90 days. The most active insider is Chang Ho Ahn (Executive), who has made 41 transactions totaling $4.7M.
Get notified when executives and directors at RNN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 28, 2019 | Benaim Ely | Executive | Option Exercise | 2,375 | $N/A | $0 | |
| Feb 28, 2019 | Nolan Lisa | Executive | Option Exercise | 1,625 | $N/A | $0 | |
| Jan 31, 2019 | Beever Charles | Executive | Purchase | 10,000 | $0.64 | $6.4K | |
| Jan 30, 2019 | Nolan Lisa | Executive | Purchase | 20,000 | $0.65 | $13.0K | |
| Jan 29, 2019 | J. Swirsky Douglas | Executive | Purchase | 50,000 | $0.63 | $31.5K | |
| Jan 29, 2019 | Gil Price Ben | Executive | Purchase | 15,000 | $0.61 | $9.2K | |
| Feb 28, 2018 | David Suzdak Peter | Executive | Option Exercise | 6,250 | $N/A | $0 | |
| Feb 28, 2018 | Benaim Ely | Executive | Option Exercise | 2,375 | $N/A | $0 | |
| Feb 28, 2018 | Nolan Lisa | Executive | Option Exercise | 1,625 | $N/A | $0 | |
| Aug 16, 2017 | David Suzdak Peter | Executive | Award | 10,000 | $1.99 | $19.9K | |
| Apr 10, 2017 | Ho Ahn Chang | Executive | Option Exercise | 250,000 | $0.31 | $77.5K | |
| Apr 10, 2017 | Ho Ahn Chang | Executive | Sale | 250,000 | $0.70 | $175.0K | |
| Mar 18, 2016 | David Suzdak Peter | Executive | Award | 60,000 | $0.32 | $19.2K | |
| Jan 12, 2015 | Ho Ahn Chang | Executive | Sale | 48,444 | $0.91 | $44.1K | |
| Jan 12, 2015 | Ho Ahn Chang | Executive | Option Exercise | 48,444 | $0.80 | $38.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 11 | $2.7M | 46.2% |
Purchase(P) | 31 | $2.1M | 36.6% |
Exercise(M) | 15 | $828.0K | 14.2% |
Payment(F) | 2 | $136.3K | 2.3% |
Award(A) | 2 | $39.1K | 0.7% |
Gift(G) | 27 | $0 | 0.0% |
Insider activity at REXAHN PHARMACEUTICALS, INC. shows mixed signals across all time. While $2.1M in purchases indicates some executive confidence,$2.7M in sales balances the picture, resulting in a modest net flow of -$557.6K.12 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Chang Ho Ahn, has transacted $4.7M during this period.